Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
When stratified by comparator groups, the pooled estimate was most favorable in monotherapy trials versus placebo (SMD 2.41, 95% CI 4.43 to 0.39), whereas the add-on designs versus the same background treatment (SMD 0.65, 95% CI 1.85 to 0.55), head-to-head comparisons versus another drug (SMD 0.19, 95% CI 0.84 to 0.45), and add-on designs versus placebo (SMD 0.65, 95% CI 1.35 to 0.06) showed more modest estimates and did not provide clear evidence of a between-group difference overall (p=0.21)
ISBN 978-0-12-391494-1
Research has focused on its facilitation of synapse formation via HGF/Met receptor signalling, with investigations suggesting neurotrophic potency orders of magnitude greater than BDNF in dendritic branching assays
Nature 392 , 565568 (1998)
US$ 23.52
US$ 21.68
US$ 21.60
US$ 24.81
US$ 21.76
US$ 21.99
